Therapeutic intervention strategie

Agent detection, remediation, and therapeutic intervention strategies Sensors and personal protective devices Environmental protection strategies... 

Liu, B., Hong, J.S. (2003) Rome of microglia in inflammation-mediated neurodegenerative diseases mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exper. Ther., 304, 1-7. 

Figure 5.2 Therapeutic interventions for decreasing colorectal mucosal bile acid exposure as a CRC chemoprevention strategy. 1) Lifestyle modifications including reduction in dietary animal fat and increased fibre intake may, at least partly, be explained by reduction in luminal primary (cholic acid [CA] and chenodeoxycholic acid [CDCA]) and secondary (deoxycholic acid [DCA] and lithocholic acid [LCA]) bile acids. 2) Reduction of secondary bile acids, which are believed to have pro-carcinogenic activity could be obtained by decreased bacterial conversion from primary bile acids. 3) Alternatively, bile acids could be sequestered by chemical binding agents, e.g. aluminium hydroxide (Al(OH)3) or probiotic bacteria. 4) Exogenous ursodeoxycholic acid (UDCA) can reduce the luminal proportion of secondary bile acids and also has direct anti-neoplastic activity on colonocytes in vitro.

In summary it can be said that besides being important in the development of therapeutic strategies to combat disease with minimal toxicity and maximal effects, drug targeting may be of interest for more basic studies on the mechanistic background of diseases and the identification of new molecules as targets for therapeutic intervention. 

Overall, the kinins are an important part of a well-organized physiological system. The various aspects and interdependencies of the kinin system have been, and continue to be, the focus of intensive research efforts in many laboratories. Many pharmaceutical companies have identified this system as an ideal site for therapeutic intervention in many inflammatory diseases. Hence, there have been many diverse approaches taken toward the discovery of antagonists (peptide and nonpeptide) of B2 and B1 receptors. This review focuses on the structure-based design strategies pursued in our laboratories during the past several years. 

Perhaps the most common model used to assess outcomes uses syngeneic mice given a subcutaneous injection of a transplantable, syngeneic tumor or xenogenic tumor injected into nude or SCID mice. These tumor models allow a broad range of outcome strategies in response to therapeutic intervention. Alternatively, models... 

---